Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer

BMC Cancer

Helgi Birgisson¹  Karolina Edlund²  Ulrik Wallin¹  Lars Påhlman¹  Hanna Göransson Kultima⁴  Markus Mayrhofer⁴  Patrick Micke²  Anders Isaksson⁴  Johan Botling²  Bengt Glimelius³  Magnus Sundström² 

[1] Department of Surgical Sciences, Colorectal Surgery, Uppsala University, Uppsala, 75185, Sweden

[2] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, 75185, Sweden

[3] Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala, 75185, Sweden

[4] Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, 75185, Sweden

关键词: Prognosis;    DNA copy number;    PIK3CA;    KRAS;    BRAF;    MSI;    Colon cancer;   

Others  :  1139042
DOI  :  10.1186/s12885-015-1144-x

 received in 2014-10-20, accepted in 2015-02-27,  发布年份 2015

【 摘 要 】

Background

Molecular alterations are well studied in colon cancer, however there is still need for an improved understanding of their prognostic impact. This study aims to characterize colon cancer with regard to KRAS, BRAF, and PIK3CA mutations, microsatellite instability (MSI), and average DNA copy number, in connection with tumour dissemination and recurrence in patients with colon cancer.

Methods

Disease stage II-IV colon cancer patients (n = 121) were selected. KRAS, BRAF, and PIK3CA mutation status was assessed by pyrosequencing and MSI was determined by analysis of mononucleotide repeat markers. Genome-wide average DNA copy number and allelic imbalance was evaluated by SNP array analysis.

Results

Patients with mutated KRAS were more likely to experience disease dissemination (OR 2.75; 95% CI 1.28-6.04), whereas the opposite was observed for patients with BRAF mutation (OR 0.34; 95% 0.14-0.81) or MSI (OR 0.24; 95% 0.09-0.64). Also in the subset of patients with stage II-III disease, both MSI (OR 0.29; 95% 0.10-0.86) and BRAF mutation (OR 0.32; 95% 0.16-0.91) were related to lower risk of distant recurrence. However, average DNA copy number and PIK3CA mutations were not associated with disease dissemination.

Conclusions

The present study revealed that tumour dissemination is less likely to occur in colon cancer patients with MSI and BRAF mutation, whereas the presence of a KRAS mutation increases the likelihood of disseminated disease.

【 授权许可】

   
2015 Birgisson et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]NORDCAN database. [Available from http://www.ancr.nu, accessed on 16/04/2013.]
• [2]Glimelius B: Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future. Ups J Med Sci 2012, 117(2):225-236.
• [3]Sobin LH, Gospodarowicz MK, Witteking C: TNM classification of malignant tumors. 7th edition. Wiley-Blackwell, Oxford; 2009.
• [4]Birgisson H, Wallin U, Holmberg L, Glimelius B: Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival. BMC Cancer 2011, 11:438. BioMed Central Full Text
• [5]Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, et al.: Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013, 24(Suppl 6):vi64-72.
• [6]Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al.: ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Ann Oncol 2012, 23(10):2479-2516.
• [7]Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27(19):3109-3116.
• [8]Cappell MS: From colonic polyps to colon cancer: pathophysiology, clinical presentation, and diagnosis. Clin Lab Med 2005, 25(1):135-177.
• [9]Higuchi T, Jass JR: My approach to serrated polyps of the colorectum. J Clin Pathol 2004, 57(7):682-686.
• [10]Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009, 9(7):489-499.
• [11]Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al.: Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319(9):525-532.
• [12]Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50(1):113-130.
• [13]Walther A, Houlston R, Tomlinson I: Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008, 57(7):941-950.
• [14]Cancer Genome Atlas N: Comprehensive molecular characterization of human colon and rectal cancer Nature 2012, 487(7407):330-337.
• [15]Rasmussen M, Sundstrom M, Goransson Kultima H, Botling J, Micke P, Birgisson H, et al.: Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol 2011, 12(10):R108. BioMed Central Full Text
• [16]Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23(3):609-618.
• [17]Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al.: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010, 28(20):3219-3226.
• [18]Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, et al.: Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol 2013, 31(14):1775-1781.
• [19]Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, et al.: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011, 103(11):863-875.
• [20]Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, et al.: Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 2009, 4(12):e8357.
• [21]Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006, 38(7):787-793.
• [22]Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, et al.: Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012, 18(8):2257-2268.
• [23]Pritchard CC, Grady WM: Colorectal cancer molecular biology moves into clinical practice. Gut 2011, 60(1):116-129.
• [24]Olshen AB, Venkatraman ES, Lucito R, Wigler M: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004, 5(4):557-572.
• [25]Rabbee N, Speed TP: A genotype calling algorithm for affymetrix SNP arrays. Bioinformatics 2006, 22(1):7-12.
• [26]Ahlbom A, Norell S: Introduction to modern epidemiology. Epidemiology Resources Inc., Chestnut Hill, MA; 1990.
• [27]Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al.: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58(1):90-96.
• [28]French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, et al.: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008, 14(11):3408-3415.
• [29]De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al.: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-762.
• [30]Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A, et al.: The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 2013, 108(10):2153-2163.
• [31]Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al.: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001, 85(5):692-696.
• [32]Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, et al.: KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 2013, 108(8):1757-1764.
• [33]Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(10):1626-1634.
• [34]Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26(3):374-379.
• [35]Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, et al.: Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cncer Res 2012, 18(17):4753-4763.
• [36]Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ: The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005, 54(9):1283-1286.
• [37]Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al.: The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010, 21(12):2396-2402.
• [38]Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al.: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011, 29(10):1261-1270.
• [39]Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, et al.: Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol 2011, 29(19):2675-2682.
• [40]Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010, 28(3):466-474.
• [41]Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al.: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005, 65(14):6063-6069.
• [42]Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al.: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013, 105(15):1151-1156.
• [43]Rosty C, Williamson EJ, Clendenning M, Walters RJ, Walsh MD, Win AK et al: Re: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2014, 106(8)
• [44]Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al.: Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012, 104(21):1635-1646.
• [45]Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al.: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012, 18(3):890-900.
• [46]Rajagopalan H, Bardelli A, Lengauer C, Kinzler K, Vogelstein B, Velculescu V: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418(6901):934.
• [47]Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, et al.: Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012, 18(23):6531-6541.
• [48]Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L: Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006, 24(15):2359-2367.
• [49]Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al.: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342(2):69-77.
• [50]Merok MA, Ahlquist T, Royrvik EC, Tufteland KF, Hektoen M, Sjo OH, et al.: Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol 2013, 24(5):1274-1282.
• [51]Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al.: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009, 27(9):1477-1484.